Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total ImmunityBio Stockholders’ Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2020		382,243,142
Beginning balance at Dec. 31, 2020	$ (118,490)	$ 38	$ 1,495,163	$ (1,615,131)	$ 122	$ (119,808)	$ 1,318
Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward]
Stock-based compensation expense	15,298		15,298			15,298
Exercise of stock options, (in shares)		690,465
Exercise of stock options	1,121		1,121			1,121
Vesting of restricted stock units (RSUs) (in shares)		235,725
Net share settlement for RSUs vesting (in shares)		(102,011)
Net share settlement for RSUs vesting	(2,624)		(2,624)			(2,624)
Other comprehensive loss, net of tax	(160)				(160)	(160)
Net loss	(80,481)			(79,614)		(79,614)	(867)
Ending balance (in shares) at Mar. 31, 2021		383,067,321
Ending balance at Mar. 31, 2021	$ (185,336)	$ 38	1,508,958	(1,694,745)	(38)	(185,787)	451
Beginning balance (in shares) at Dec. 31, 2021	397,830,044	397,830,044
Beginning balance at Dec. 31, 2021	$ (243,913)	$ 40	1,719,704	(1,961,921)	4	(242,173)	(1,740)
Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward]
Stock-based compensation expense	$ 10,024		10,024			10,024
Exercise of stock options, (in shares)	14,767	14,767
Exercise of stock options	$ 74		74			74
Vesting of restricted stock units (RSUs) (in shares)		177,783
Net share settlement for RSUs vesting (in shares)		(65,832)
Net share settlement for RSUs vesting	(372)		(372)			(372)
Other comprehensive loss, net of tax	(371)				(371)	(371)
Net loss	$ (102,998)			(102,826)		(102,826)	(172)
Ending balance (in shares) at Mar. 31, 2022	397,956,762	397,956,762
Ending balance at Mar. 31, 2022	$ (337,556)	$ 40	$ 1,729,430	$ (2,064,747)	$ (367)	$ (335,644)	$ (1,912)